Mylan (NSDQ:MYL) and Biocon announced today that a European Medicines Agency committee has recommended approval for its biosimilar insulin glargine, Semglee.
The committee’s positive opinion brings the product one step closer to approval. The European Commission is slated to make a final decision in April.
Get the full story at our sister site, Drug Delivery Business News.
The post European committee backs Mylan’s insulin glargine biosimilar appeared first on MassDevice.
from MassDevice http://ift.tt/2FsSWoR
Cap comentari:
Publica un comentari a l'entrada